STEM CELLS USED FOR AGE-RELATED MACULAR DEGENERATION
Dr Jenna Hall
Senior Research Associate
University of Melbourne, Victoria, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | January 2025
Dr. Jenna Hall is a passionate and accomplished biologist with expertise in induced pluripotent stem cell (iPSC) culture, disease modelling, and high-throughput automated systems. She recently earned her PhD from the University of Melbourne, where her research focused on using iPSC-derived retinal pigment epithelium (RPE) cells to study age-related macular degeneration. Dr Hall’s technical skillset spans manual and automated cell reprogramming and differentiation, quantitative microscopy-based phenotyping, and large scale -omics analysis.
Dr Hall was awarded a highly competitive and sought after Australian Research Council Centre for Personalised Therapeutics and Technologies (ARC CPTT) scholarship which, in addition to funding her PhD, included an industry internship with a leading life sciences consultancy firm. Her internship with Biointelect allowed her to contribute to strategic projects addressing key challenges in Australia’s biotechnology ecosystem. Her white papers on the country’s vaccine and drug value chain, as well as anti-obesity medication, demonstrated her ability to combine scientific knowledge with commercial insights to influence policy and improve pandemic preparedness.
Dr Hall has over four years of industry experience, including her time at the New York Stem Cell Foundation, where she collaborated with engineers and data scientists to develop scalable workflows for cell reprogramming, downstream differentiation, and automated maintenance. For her next career step, Dr Hall is hoping to secure a role in a fertility research lab.
-
Tyrosine Kinases in cancer recurrence
Dr Yu Yu leads the Oncology and Gynaecology Research Program at Curtin Medical Research Institute . Dr Yu is also a senior research fellow at Curtin Medical School.
Dr Yu Yu’s laboratory is working on better ways to treat cancers, particularly ovarian cancers which are resistant to conventional chemotherapy. The aims are for better informed treatment choice and reducing unnecessary exposure to ineffective chemotherapy and its potential adverse effects.
-
Development of novel analytical and diagnostic tools using nanotechnology and microfluidics
Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.
Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.
-
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
